Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial

Fig. 2

Values of left ventricle global longitudinal strain (GLS) at baseline (0), 1 month and 6 months follow-up visits during empagliflozin (red) or sitagliptin (blue) treatment. The population was divided in two subgroups depending on baseline GLS values above (continuous line) or below (dotted lines) median (median for empagliflozin group: GLS 16.4%; median for sitagliptin group: GLS 16.0%). The star indicates a statistically significant time*treatment effect at ANOVA for repeated measures

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840